Tactile Medical Inks Exclusive VA/DoD Distribution Deal for Wearable Compression Device
TCMD has more than doubled off its 52-week low of $9.415.
Summary
Tactile Medical secured exclusive U.S. distribution rights for ElastiMed's MyoSleeve, a discreet, battery-powered compression device, targeting VA and DoD patients. The deal includes a $3 million upfront payment and minimum purchase obligations, expanding Tactile's portfolio into earlier-stage chronic swelling treatment. This follows strong Q1 2026 results with 23% revenue growth, and leverages the company's existing sales infrastructure to drive commercialization. The agreement adds a differentiated, FDA-cleared product that complements Tactile's pneumatic compression therapies, potentially opening a new revenue stream within government healthcare channels.
At the time of this announcement, TCMD was trading at $29.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $672.9M. The 52-week trading range was $9.42 to $37.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.